During the last session, Unity Biotechnology Inc (NASDAQ:UBX)’s traded shares were 0.67 million, with the beta value of the company hitting 1.08. At the end of the trading day, the stock’s price was $2.38, reflecting an intraday loss of -7.39% or -$0.19. The 52-week high for the UBX share is $3.10, that puts it down -30.25 from that peak though still a striking 60.5% gain since the share price plummeted to a 52-week low of $0.94. The company’s market capitalization is $40.11M, and the average intraday trading volume over the past 10 days was 0.52 million shares, and the average trade volume was 196.14K shares over the past three months.

Unity Biotechnology Inc (UBX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. UBX has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.4.

Unity Biotechnology Inc (NASDAQ:UBX) trade information

Unity Biotechnology Inc (UBX) registered a -7.39% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -7.39% in intraday trading to $2.38, hitting a weekly high. The stock’s 5-day price performance is 40.83%, and it has moved by 147.97% in 30 days. Based on these gigs, the overall price performance for the year is 36.00%. The short interest in Unity Biotechnology Inc (NASDAQ:UBX) is 0.24 million shares and it means that shorts have 2.29 day(s) to cover.

Unity Biotechnology Inc (UBX) estimates and forecasts

Statistics show that Unity Biotechnology Inc has outperformed its competitors in share price, compared to the industry in which it operates. Unity Biotechnology Inc (UBX) shares have gone up 64.14% during the last six months, with a year-to-date growth rate more than the industry average at 47.08% against 16.50.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 36.93%. While earnings are projected to return 49.22% in 2025, the next five years will return 29.27% per annum.

UBX Dividends

Unity Biotechnology Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Unity Biotechnology Inc (NASDAQ:UBX)’s Major holders

Unity Biotechnology Inc insiders own 1.31% of total outstanding shares while institutional holders control 20.21%, with the float percentage being 20.48%.

Also, the Mutual Funds coming in first place with the largest holdings of Unity Biotechnology Inc (UBX) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 395.99 shares. This amounts to just over 2.35 percent of the company’s overall shares, with a $0.94 million market value. The same data shows that the other fund manager holds slightly less at 194.78, or about 1.16% of the stock, which is worth about $0.46 million.